Stockwinners Market Radar for November 17, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

18:50 EST Sundial Growers, Nova Cannabis mutually terminate implementation agreement - Sundial Growers (SNDL) and Nova Cannabis announced the mutual decision to terminate the implementation agreement, dated December 20, 2022, as amended, concerning their previously-announced strategic partnership. SNDL and Nova reaffirm their strong commitment to their ongoing partnership under the management and administrative services agreement. "We are dedicated to building a consumer-centric, regulated products business model within a complex regulatory environment," said Zach George, CEO of SNDL. "The synergy between our companies has already demonstrated great results, and combined efforts and shared vision are key drivers in this journey towards market leadership. SNDL remains committed to being a strong financial partner to Nova, with a focus on fostering sustainable business growth and development." In connection with the termination of the Implementation Agreement, SNDL and Nova have extended the maturity date of Nova's credit facility with SNDL to March 31, 2024.

18:16 EST Huntington Ingalls awarded U.S. Navy contract with potential $185M value - Huntington Ingalls announced that its Ingalls Shipbuilding division received a cost-plus-award fee contract from the U.S. Navy for follow yard support of the Navy's Arleigh Burke-class destroyer program. This contract, which allows for the continuation of key technical management and support functions that enable coordinated production of DDGs under existing construction contracts, includes four option years with a total potential contract value of $185M if all options are exercised. "This is another exciting opportunity for our shipbuilders to demonstrate their versatility in handling all aspects of shipbuilding," Ingalls Shipbuilding DDG 51 Program Manager Ben Barnett said. "We are honored to provide this support to our Navy customer and the nation's defense."

17:24 EST 10x Genomics wins patent infringement case against NanoString - 10x Genomics (TXG) announced that a jury in the U.S. District Court for the District of Delaware has reached a unanimous verdict in favor of 10x Genomics in the patent infringement suit 10x filed against the GeoMx products sold by NanoString Technologies (NSTG). In awarding over $31M in damages, the jury found that NanoString's GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection willfully infringe all seven asserted patents owned by Prognosys and exclusively licensed to 10x Genomics. The jury awarded over $31M in damages for sales of the infringing GeoMx products from May 6, 2021 through October 13, 2023. In post-trial proceedings, 10x intends to seek (a) ongoing royalties for NanoString's willful infringement by sales of the GeoMx products after October 13, 2023; (b) treble damages and attorney's fees for NanoString's willful infringement; (c) a permanent injunction barring the making, using, selling and offering for sale the GeoMx products in the United States; and (d) pre- and post-judgment interest.

17:03 EST Oceaneering names Catherine Dunn as Chief Accounting Officer - Oceaneering International announced the promotion of Catherine Dunn to Vice President and Chief Accounting Officer, effective December 1, 2023. Dunn joined Oceaneering in June 2002 and has served as Corporate Controller since January 2012. Her career includes significant financial and public accounting experience in the energy industry. Prior to joining Oceaneering, Dunn was with Arthur Anderson.

16:49 EST Leo Holdings, World View mutually agree to terminate business combination - World View and Leo Holdings Corp. II announced that they intend to mutually agree to terminate their previously announced business combination agreement. Over the course of 2023, World View received strong interest from potential investors. However, given challenging market conditions, World View and Leo jointly determined that it was the best course of action at this time to not proceed with their previously announced transaction. In view of the expected termination of the Business Combination Agreement, Leo determined that it will not be able to consummate an initial business combination within the time period required by its amended and restated memorandum and articles of association. As such, Leo intends to dissolve and liquidate in accordance with the provisions of the Articles and will redeem all of the outstanding Class A Ordinary Shares, par value $0.0001 per share, on or about December 4, 2023. On November 17, 2023, the Public Shares were suspended from trading on the New York Stock Exchange and represent the right to receive the per-share redemption price for the Public Shares of approximately $10.95, based on the amount in the trust account established in connection with Leo's initial public offering as of November 15, 2023. In accordance with the terms of the Articles, Leo expects to retain $100,000 of the interest earned on the Trust Account to pay dissolution expenses. The Per-Share Redemption Amount will be payable to the holders of the Public Shares upon presentation of their respective share or unit certificates or other delivery of their shares or units to Leo's transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the Per-Share Redemption Amount. There will be no redemption rights or liquidating distributions with respect to Leo's warrants. Leo's initial shareholders have waived their redemption rights with respect to the outstanding Class B ordinary shares, par value $0.0001 per share, issued prior to Leo's initial public offering. As of November 12, 2023, Leo ceased all operations except those required to wind up Leo's business. Leo expects that The New York Stock Exchange will file a Form 25 with the U.S. Securities and Exchange Commission to delist its securities.

16:45 EST Churchill Capital Corp VI to redeem public shares - Churchill Capital Corp VI announced that its board of directors has determined to redeem all of its outstanding shares of Class A common stock, par value $0.0001 because the company will not consummate an initial business combination within the time period required by its Amended and Restated Certificate of Incorporation. The previously disclosed non-binding letter of intent has been terminated in accordance with its terms. The per-share redemption price for the public shares will be approximately $10.49. The last day that the company's securities will trade on the New York Stock Exchange will be December 1, 2023. Effective as of the close of business on December 4, 2023, the public shares will be deemed cancelled and will represent only the right to receive the Redemption Amount.

16:24 EST Masimo W1 Medical Watch receives FDA 510k clearance - Masimo announced the Masimo W1 medical watch has received FDA 510(k) clearance for over-the-counter and prescription use. Masimo W1 is the first FDA-cleared watch to provide continuous real-time oxygen saturation and pulse rate for OTC and Rx use. The FDA clearance expands the indications for the Masimo W1 in the U.S. as a medical device for use by adults in hospitals, clinics, long-term care facilities, and in the home. Developed to be comfortable and lifestyle-friendly, the Masimo W1 medical watch empowers users with untethered continuous pulse oximetry as they move about their lives - no matter where they are.

16:16 EST Microsoft says it remains committed to OpenAI's team following CEO departure - In a statement, a Microsoft spokesperson said the company remains committed to OpenAI's team following the news of CEO Sam Altman's departure from OpenAI. Microsoft has had a long-term partnership with OpenAI that was extended in January of 2023.

16:16 EST Clearmind Medicine receives Nasdaq delisting notice - Clearmind Medicine announced receipt of a Staff Delisting Determination from the Listing Qualifications Department of the Nasdaq Stock Market, LLC. The company was notified that Nasdaq has determined to delist the company's securities from the Nasdaq Capital Market for failure to maintain a minimum bid price of $1.00 per share for thirty consecutive business days in accordance with Nasdaq Listing Rule 5550(a)(2). The company plans to appeal the Staff's determination to a Hearings Panel. A hearing request will stay the suspension of the company's securities and the filing of the Form 25-NSE pending the panel's decision.

16:08 EST Medavail receives Nasdaq notification of non-compliance - MedAvail Holdings announced that on November 16, 2023, the Company received a delinquency notification letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company was not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of its failure to have timely filed its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023 with the Securities and Exchange Commission. The delinquency notification letter provides that, under Nasdaq rules, the Company now has 60 calendar days to submit to Nasdaq a plan to regain compliance in accordance with Nasdaq's listing requirements. If the Company's plan is accepted, Nasdaq may grant the Company up to 180 days, or until May 13, 2024, for the Company to regain compliance. If Nasdaq does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a Nasdaq hearings panel. The delinquency notification letter has no immediate effect on the listing of the Company's common stock on the Nasdaq Capital Market.

16:06 EST Quantum announces Nasdaq notification over delayed 10-Q filing - Quantum Corporation announced that it received a notice from the Listing Qualifications staff of the Nasdaq Stock Market LLC on November 14, 2023 stating that the company is not in compliance with Nasdaq Listing Rule 5250(c)(1) as a result of the company's delay in filing its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 with the Securities and Exchange Commission.

16:05 EST Qorvo chairman Quinsey to retire upon expiration of his term - In a regulatory filing, Qorvo said that chairman Ralph Quinsey informed the company of his decision not to stand for reelection and to retire from the Board upon the expiration of his term at the company's 2024 Annual Meeting of Stockholders. Quinsey also informed the Board that he would step down as Chair and Lead Independent Director as of November 13. Quinsey has advised the company that his decision to retire is to address other professional and personal commitments and is not due to any disagreement with the company on any matter relating to company operations, policies or practices. The Board and company management express their deep appreciation to Quinsey for his dedicated service and significant contributions. The Board has named Dr. Walden C. Rhines as the new Chair of the Board and Lead Independent Director. Dr. Rhines has served as a director of the Company since 2015.

15:41 EST OpenAI announces Sam Altman will depart as CEO, leave board - The board of directors of OpenAI, Inc, the 501(c)(3) that acts as the overall governing body for all OpenAI activities, announced that Sam Altman will depart as CEO and leave the board of directors. Mira Murati, the company's Chief Technology Officer, will serve as interim CEO, effective immediately. "Altman's departure follows a deliberative review process by the board, which concluded that he was not consistently candid in his communications with the board, hindering its ability to exercise its responsibilities. The board no longer has confidence in his ability to continue leading OpenAI," the company said. In a statement, the board of directors said: "OpenAI was deliberately structured to advance our mission: to ensure that artificial general intelligence benefits all humanity. The board remains fully committed to serving this mission. We are grateful for Sam's many contributions to the founding and growth of OpenAI. At the same time, we believe new leadership is necessary as we move forward. As the leader of the company's research, product, and safety functions, Mira is exceptionally qualified to step into the role of interim CEO. We have the utmost confidence in her ability to lead OpenAI during this transition period." As a part of this transition, Greg Brockman will be stepping down as chairman of the board and will remain in his role at the company, reporting to the CEO, the company noted. OpenAI is 49% owned by Microsoft and that latter's shares are down about 2% in afternoon trading following the news. Reference Link

14:04 EST Spirit Airlines up 20% in Friday afternoon trading - Shares of Spirit Airlines (SAVE) are up $2.09, or 20%, to $12.53 near 2 pm ET on Friday while shares of JetBlue (JBLU) are down 4% to $4.17.

13:15 EST Donaldson authorizes repurchase of up to 12M shares - Donaldson Company announced that its board of directors declared a regular cash dividend of 25c per share and authorized a new share repurchase program. The dividend is payable December 20 to shareholders of record on December 5. Additionally, Donaldson's board authorized the repurchase of up to 12M shares of its common stock, or approximately 10% of its outstanding shares. The new repurchase authorization replaces the existing authority that was approved in May 2019. To date, the company has repurchased approximately 11M shares under the prior authorization of 13M shares.

13:02 EST Baker Hughes reports U.S. rig count up 2 to 618 rigs - Baker Hughes reports that the U.S. rig count is up 2 from last week to 618 with oil rigs up 6 to 500, gas rigs down 4 to 114 and miscellaneous rigs unchanged at 4. The U.S. Rig Count is down 164 rigs from last year's count of 782 with oil rigs down 123, gas rigs down 43 and miscellaneous up 2. The U.S. Offshore Rig Count is unchanged at 19, up 2 year-over-year. The Canada Rig Count is down 3 from last week to 196, with oil rigs down 2 to 123, and gas rigs down 1 to 73. The Canada Rig Count is down 5 from last year's count of 201, with oil rigs down 12, and gas rigs up 7.

12:40 EST Timber Pharmaceuticals Inc trading halted, news pending

12:00 EST Spectrum Brands falls -9.5% - Spectrum Brands is down -9.5%, or -$7.32 to $69.58.

12:00 EST Brookdale Senior Living rises 12.6% - Brookdale Senior Living is up 12.6%, or 57c to $5.09.

12:00 EST Gap rises 28.5% - Gap is up 28.5%, or $3.90 to $17.57.

11:44 EST FTC sues to block Tenet sale of John Muir Health - The Federal Trade Commission sued to block John Muir Health's proposed $142.5M deal to acquire sole ownership of San Ramon Regional Medical Center from current majority owner Tenet Healthcare THC), saying the deal will drive up health care costs. The Commission issued an administrative complaint and authorized a lawsuit in federal court alleging the proposed acquisition "will eliminate head-to-head competition between John Muir Health and nearby San Ramon Regional Medical Center." Reference Link

10:42 EST FingerMotion adding Benzinga to lawsuit related to short seller's report - FingerMotion provided a litigation update to the market regarding its newly filed lawsuit against Capybara Research, stating: "On October 19, 2023, FingerMotion filed a federal lawsuit in the United States District Court for the Southern District of New York against Capybara, a firm recently created and that enjoyed anonymity through various social media postings without any trail as to ownership while antagonizing our retail investment community by posting lewd and unprofessional graphics, intended to further embarrass the Company. After weeks of investigatory work by the Company's litigation counsel as well as cooperation of third parties, the Company is pleased to announce that its attorneys have been successful in identifying the person responsible for the malicious article and is now taking all steps necessary to add the person's name to the lawsuit and to serve that individual. FingerMotion also announced that it is also adding to its federal lawsuit the social media news outlet Benzinga for republishing, and continuing to republish the Capybara report and other false reports that continue to harm FingerMotion's retail investment community." Martin Shen, CEO of FingerMotion, stated: "We are committed to legally pursuing the Capybara short and distort campaign as well as all media outlets that irresponsibly reported the false, misleading and defaming Capybara Report."

10:12 EST CPKC makes statement on draft decree on passenger service - Canadian Pacific Kansas City issued a statement on the draft decree concerning passenger rail service in Mexico issued by the Mexican Federal Government: "CPKC is reviewing the draft decree and remains directly engaged with the Mexican Federal Government regarding potential passenger rail service on certain existing freight rail corridors. CPKC de Mexico has previously reached an agreement with the Mexican Federal Government to perform a study of what is required for the proposed new passenger rail service on the right of way of the corridor between Mexico City and Queretaro. The draft decree, which is expected to become effective by November 20, 2023, also identifies the San Luis Potosi-Monterrey-Laredo corridor for the proposed passenger rail service. As required by our concession, CPKC de Mexico will work closely with the Mexican Federal Government to evaluate passenger service on that corridor. The draft decree emphasizes that the public freight rail service will be respected and as such, we do not expect an adverse impact on our concession. CPKC has extensive experience hosting passenger rail services in multiple locations across its network in the United States and Canada while efficiently managing freight service."

10:00 EST Beazer Homes falls -8.0% - Beazer Homes is down -8.0%, or -$2.41 to $27.83.

10:00 EST Atkore falls -9.1% - Atkore is down -9.1%, or -$12.30 to $122.93.

10:00 EST Tenet Healthcare rises 13.1% - Tenet Healthcare is up 13.1%, or $7.63 to $65.77.

09:57 EST Presto implements reduction in force of full-time employee base by 17% - Presto will take further steps in its ongoing efforts to reduce costs, improve profitability, and streamline operations by implementing a reduction in force of its global full-time employee base by approximately 17%. The Company estimates that this initiative, along with other cost-saving initiatives, will reduce monthly expenditures by approximately $0.4 million, rising to approximately $1.2 million after approximately eight months.

09:52 EST Curis trading halted, volatility trading pause

09:47 EST Atkore falls -9.3% - Atkore is down -9.3%, or -$12.53 to $122.70.

09:47 EST Natural Grocers rises 8.6% - Natural Grocers is up 8.6%, or $1.10 to $13.90.

09:47 EST Gap rises 18.4% - Gap is up 18.4%, or $2.52 to $16.19.

09:46 EST AT&T to create standalone managed cybersecurity services business - AT&T announces an agreement to create a standalone managed cybersecurity services business, and a capital investment in that business from WillJam Ventures, a Chicago-based investor with "deep cybersecurity industry and leadership experience." At close, the new cybersecurity joint venture will hold select security software solutions, associated managed security operations and security consulting resources. AT&T will retain an ownership stake and board representation in the new entity. "This arrangement will enable AT&T to continue offering Managed Security Services, while simultaneously focusing on enhanced network-based security capabilities," the company stated. AT&T expects the transaction, which is subject to regulatory reviews and customary closing conditions, to close in 1Q24. Additional terms of the transaction were not disclosed. Reference Link

09:07 EST Vivakor announces all proposals approved at Special Meeting - Vivakor announced that all of its proposals were approved and with greater than 90% voted for each proposal at its Special Meeting of Shareholders held on November 10, 2023. The following proposals were all approved: Acquisition Stock Issuance, pursuant to the Membership Interest Purchase Agreement; CEO Compensation Shares; Vivakor, Inc. 2023 Equity and Incentive Plan; Amendment to Articles of Incorporation to amend its federal forum selection provision; Amendment to Articles of Incorporation to increase the Company's authorized number of shares of Common Stock to 200 million; Adjournment of the stockholder meeting.

09:05 EST Scilex announces issuance of second new patent in U.S. for ZTlido - Scilex Holding announced that the U.S. Patent and Trademark Office has issued a second new patent, No. 11,786,455, further strengthening the Company's intellectual property position and coverage for its lead commercial product, ZTlido 1.8%, which will expire in 2031. The Patent, titled "Non-aqueous Patch," covers a non-aqueous lidocaine patch with certain specifications, as well as a method of relieving pain through the application of a non-aqueous lidocaine-containing patch. These two new issued patents No. 11,786,455 and No. 11,793,766 will be listed in the U.S. Food and Drug Administration's Orange Book in connection with ZTlido.

09:04 EST DTE Energy to reduce Power Supply Cost Recovery mechanism - DTE Energy's customers will soon see a decrease in their electric bills. DTE will be reducing the Power Supply Cost Recovery mechanism, which represents the actual cost of the fuel and other sources the company uses to produce electricity, by approximately $300 million annually. This reduction will go into effect December 1 and will reduce average electric bills for residential customers by approximately $5 per month.

09:03 EST Edible Garden deploys grant funded technology from BRISEA - Edible Garden announced a partnership with high-tech firm BRISEA Group Inc, to deploy BRISEA's nanobubble generator demo unit at the Company's Belvidere, New Jersey facility.J im Kras, CEO, commented, "We are pleased to partner with BRISEA Group Inc., a leading provider of end-to-end prototyping services for environmental applications including water, air, and solid waste treatment, which was granted approval by the NJ Economic Development Authority (NJEDA) for the Demo Project Grant as part of the recently funded NJEDA CSIT Pilot Clean Tech Demonstration Grant Program, for a two-year nanobubble generator demonstration and evaluation, a major milestone in the study of nanobubble technology. The deployment of the agricultural nanobubble generator unit at our Belvidere, New Jersey facility aims to demonstrate both the capabilities and the potential impact of the innovative technology. Additionally, we are confident that this collaboration will generate valuable data that can be effectively integrated with our ongoing partnership involving NJIT, the USDA, and the EPA examining the effects of nanobubble technology on the safety of fresh produce and the enhancement of processing methods."

09:02 EST Boston Scientific sees Relievant acquisition 'slightly accretive' to EPS in 2025 - Boston Scientific announced the close of its acquisition of Relievant Medsystems. The acquisition includes an upfront cash payment of $850M and undisclosed additional contingent payments based on sales performance over the next three years. On an adjusted basis, the transaction is expected to be immaterial to adjusted earnings per share in 2024, slightly accretive in 2025 and increasingly accretive thereafter. On a GAAP basis, the transaction is expected to be more dilutive due to amortization expense and acquisition-related charges.

09:01 EST Sprout Social appoints Morris as CMO - Sprout Social announced the appointment of Scott Morris to chief marketing officer, CMO, effective December 4, 2023. As CMO, Morris will oversee Sprout's global marketing organization and be a key contributor to Sprout's continued growth. Morris brings more than 25 years of experience leading key strategic marketing initiatives at both B2B and B2C tech companies. Prior to Sprout, Morris held executive leadership positions at Zendesk including SVP Global Marketing and Acting CMO.

08:48 EST Presidio Property Trust board approves share repurchase plan - Presidio Property Trust announced that its Board of Directors has approved a share repurchase plan authorizing the Company to repurchase up to $6 million of its outstanding shares of Series A Common Stock and up to $4 million of its outstanding shares of Series D Preferred Stock. Under the share repurchase program, the shares may be repurchased from time to time using a variety of methods, which may include open market transactions, privately negotiated transactions or otherwise, all in accordance with the rules of the Securities and Exchange Commission and other applicable legal requirements.

08:42 EST Ayr Wellness says cultivation setback in Florida to impact Q4 revenue by $4M-$6M - As part of its Q3 earnings yesterday, Ayr Wellness stated: "The Company remains committed to further improving its financial health and positioning itself for sustainable, profitable growth across its footprint. Due to the modest sequential revenue decline in the third quarter, coupled with the temporary cultivation setback in Florida that will impact fourth quarter revenue by approximately $4-6 million, the Company no longer anticipates growth for the second half of 2023 over first half levels. The Company now expects revenue to be essentially flat in the fourth quarter compared to the third quarter, and to maintain an adjusted EBITDA margin of 25% in the fourth quarter."

08:34 EST NewLake tenant Calypso closes on sale to Canvas Acquisition - NewLake Capital Partners announced that Hero Diversified Associates has sold, Calypso Enterprises, which is a NewLake tenant, to Canvas Acquisition Corporation. In connection with the closing of the sale of Calypso and under the terms of the revised lease agreement, NewLake has agreed to provide up to $3 million in tenant improvements and has received a six-month rent escrow. NewLake also provided Canvas the option to purchase the property at NewLake's cost basis from December 1, 2024 through December 31, 2025. "Interest during Calypso's sale process demonstrates the quality of the facility and the business opportunity in limited license states, particularly Pennsylvania where adult-use is on the horizon. Canvas will bring brands, products, and relationships to the Pennsylvania market, significantly improving the competitiveness of our tenant," stated Anthony Coniglio, NewLake's President and Chief Executive Officer. "Additionally, the acquirors financial profile as the new lease guarantor is improved from HDAI. We are appreciative of our partners at HDAI and are excited to work with our new partners at Canvas."

08:32 EST SRM Entertainment's Sip with Me cups available on Amazon - SRM Entertainment (SRM) announces its official launch on Amazon (AMZN). Sip with Me patented children's cups featuring Smurfs & Zoonicorn franchise characters along with SRM's Trend Animal collection are now available on Amazon, the world's largest online marketplace. This strategic move not only marks a significant milestone for SRM but also opens up new avenues for our customers to purchase their favorite cups.

08:32 EST Gulf Resources announces its flood prevention plan - Gulf Resources announced that it has recently initiated its preventive measures for safeguarding its bromine facilities. To mitigate damages in the future, the Company has commenced a flood prevention initiative. The strategy involves the renovation of the channels of four major rivers within our mining area, encompassing the tributary of the Mihe River. The aim is to prevent flooding that could harm the wells, aqueducts and crude salt pans at our plant. The projected expenditure for this initiative amounts to $50,497,652. As of the third quarter, ending on September 30, 2023, the disbursed $15,149,296 for the initial phase of this project. Apart from reducing risk to surrounding regions, the company anticipates three notable advantages from this flood prevention plan. It is expected to: enhance the probability of obtaining approval to reopen factories #2 and #10; enable the drilling of additional wells across five operating factories, and mitigate the risks and associated expenses related to future storms-induced flooding.

08:19 EST CBRE Group appoints CEO Robert Sulentic to chair - CBRE Group announced that its board of directors has appointed CEO Robert Sulentic to the additional role of chair of the board of directors, effective immediately. Sulentic, who has served as president and CEO of CBRE since December 2012, succeeds Brandon Boze, who has served as chair since May 2018 and will remain on the board.

08:15 EST Diversified Healthcare Trust CEO Jennifer Francis to retire - Diversified Healthcare Trust (DHT) announced that Christopher Bilotto has been appointed president and CEO, effective January 1, 2024. Bilotto is an executive VP of RMR Group (RMR), overseeing portfolio management for all office, industrial and retail properties managed by RMR and hotel and senior living asset management, as well as development and redevelopment across the United States. Bilotto succeeds Jennifer Francis who is retiring from RMR on July 1, 2024 and therefore resigning from her executive officer positions at DHC and RMR, effective December 31.

08:13 EST Permian Basin Royalty Trust declares monthly distribution of 15.7171c per unit - Argent Trust Company, as Trustee of the Permian Basin Royalty Trust, declared a cash distribution to the holders of its units of beneficial interest of 15.7171c per unit, payable on December 14, 2023, to unit holders of record on November 30, 2023. This month's distribution increased from the previous month due to an increase in oil and gas pricing for the period along with a decrease in CAPEX that contributed to the NPI distribution from Blackbeard Operating on the Waddell Ranch Properties for the month of September.

08:09 EST Pioneer Power to provide e-Boost EV charging system to MACAW Energies - Pioneer Power Solutions announced that it will provide an e-Boost electric vehicle charging solution to MACAW Energies, an integrated company that will power the system with its low-carbon liquefied natural gas produced with natural gas that otherwise would be flared or wasted. The e-Boost solution will be deployed at MACAW's pilot project in Texas, which aims to accelerate EV adoption of fleet customers through an ultra high-speed charging hub for MACAW's EVs powered on low-carbon, flare gas technology. Pioneer Power's innovative e-Boost solution will help MACAW develop its first EV charging hub, including direct-current ultra-fast chargers, capable of reaching power levels up to 300 kW for a single vehicle - making a full charge possible for large EVs in less than an hour. Alternatively, e-Boost can charge up to four EV vehicles at one time, delivering 360 KW of combined power, exceeding the standards set by NEVI for highway EV charging requirements. The LNG to power the e-Boost solution will be delivered to MACAW's EV charging hub as an affordable and clean energy source. MACAW will utilize its industry leading liquefaction technology to treat natural gas that would otherwise be flared and wasted to produce LNG and efficiently transport the fuel to deliver low carbon energy that will power the e-Boost solution for off-grid EV charging. Future MACAW EV charging hubs are planned for various locations throughout the US later in 2024.

08:07 EST FSD Pharma announces distribution date for Celly shares - FSD Pharma announced that, further to its press release dated November 7, 2023, that its distribution date for the contemplated plan of arrangement is November 29, 2023. Subject to the satisfaction of all applicable closing conditions of the Arrangement, common shares in the capital of Celly Nutrition Corp. will be distributed to FSD Pharma Securityholders of record as of November 28, 2023 on the Distribution Date. The ex-dividend date is November 27, 2023. Holders of all shares in the capital of FSD Pharma and warrants exercisable for the purchase of class B subordinate voting shares, provided the applicable warrant certificate entitles the holder thereof to receive distributions substantially similar to those received by holders of class B subordinate voting shares on the Record Date will be eligible to receive Celly Nu Shares on the Distribution Date pursuant to Arrangement. As a result of the Arrangement, FSD Pharma Securityholders are expected to receive one Celly Nu Share in respect of FSD Pharma Share or FSD Pharma Distribution Warrant that is held by such FSD Pharma Securityholder. The Company expects that this will result in an aggregate of approximately 45,694,621 Celly Nu Shares being distributed to the FSD Pharma Securityholders and an aggregate of approximately 154,305,379 Celly Nu Shares retained by the Company, in each case assuming that the number of FSD Pharma Shares and FSD Pharma Distribution Warrants remains unchanged between today and the Distribution Date. It is expected that DRS statements representing the Celly Nu Shares to which the registered FSD Pharma Securityholders are entitled to under the Arrangement will be sent out on or about the Distribution Date. The special meeting of the FSD Pharma Securityholders to vote on the Arrangement is scheduled to be held on November 20, 2023. Additionally, the final hearing at the Ontario Superior Court of Justice to approve the Arrangement is scheduled for November 24, 2023.

08:05 EST Humacyte announces two presentations at VEITHsymposium on HAV - Humacyte announced the presentation of positive V005 Phase 2/3 clinical trial results of the investigational Human Acellular Vessel, HAV, in the treatment of vascular trauma, as well as results from the treatment of wartime injuries in Ukraine. Results showed the HAV had higher rates of patency, and lower rates of amputation and infection, compared to historic synthetic graft benchmarks. Humacyte plans to file a Biologics License Application, BLA, for the HAV for an indication in vascular trauma patients with the U.S. Food and Drug Administration, FDA, during the current quarter. The V005 trial was a single-arm study conducted in the United States and Israel in patients with arterial injuries resulting from gun shots, workplace injuries, car accidents, or other traumatic events for whom the standard of care, saphenous vein, was not feasible or available to use as a bypass graft. Primary patency for the HAV was 81.2% for the extremity patients, although no comparison to synthetic graft primary patency was possible since this measure was not reported in the benchmark publications. The HAV also demonstrated lower amputation rates, with a rate of 9.8% for extremity patients compared to 24.3% historically reported for synthetic grafts. Furthermore, the HAV demonstrated lower rates of infection, with a rate of 2.0% for the extremity patients compared to 8.4% historically reported for synthetic grafts. In the V005 trial, the most common reasons reported by clinicians for using the HAV instead of the standard of care, saphenous vein, was the need to avoid the time required to harvest saphenous vein, the quality of the patient's vein, and concomitant injuries to the vein, suggesting that the ready, off-the-shelf feature of the HAV has the potential to save valuable time for surgeons in the restoration of blood flow. The FDA has advised Humacyte to include in the BLA submission patient outcomes from a humanitarian program conducted in Ukraine. Results for the 16 extremity patients from Ukraine who provided consent for use of their results in the BLA filing were also presented at the meeting, a set of data known as the "V017 trial." The rate of success for treatment of patients with the HAV in the V017 trial was high, with a 30-day secondary patency of 93.8%, zero amputations, and zero cases of infection of the HAV. The results of a meta-analysis combining the V005 and V017 trials concluded that the HAV demonstrated higher patency with a 30-day secondary patency rate of 91.5% for the extremity patients compared to 78.9% historically reported for synthetic grafts. There were no unexpected safety signals for the HAV in the V005 and V017 studies. Common adverse events reported were anemia, vascular graft thrombosis, blood loss anemia, pyrexia, thrombocytopenia, constipation, nausea peripheral edema, and tachycardia. There were four deaths among the extremity patients in the V005 trial, and zero deaths in the V017 trial. There were no deaths among extremity patients in the V005 trial attributed to the HAV.

08:04 EST Eli Lilly to construct high-tech manufacturing site in Germany - Eli Lilly and Company announced plans to construct a new $2.5B high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral product and device manufacturing network and support an increased demand for Lilly's medicines, including its diabetes and obesity portfolio. The company has launched 21 treatments since 2014 and plans to launch several more in the coming years. With extensive experience across the pharmaceutical industry, Germany's workforce will play a vital role in bolstering Lilly's incretin supply when the new site is operational beginning in 2027. The site in Alzey will employ up to 1,000 highly skilled workers such as engineers, operators and scientists, who will leverage state-of-the-art technology, including automation and high-speed manufacturing lines, to produce life-changing medicines. In addition, an estimated 1,900 jobs will be created during construction, which is scheduled to begin in 2024. Lilly's investment in Alzey is contingent upon finalization of government permitting and local approvals. The company is also announcing an investment of up to $100M to dramatically increase its footprint in Germany's early-stage biotech ecosystem. These investments will focus on biotech and the life sciences venture capital funds - expanding Lilly's incubator and accelerator engagements, and strengthening Lilly's ties and activities with world-renowned academic and innovation partners. With these investments, Lilly will pursue strategic partnerships and collaborations utilizing a variety of models that meet a range of business needs, including capital and equity investments; world-class lab space; and outstanding research and development capabilities and expertise to help accelerate innovative medicines that meet the needs of people globally.

08:02 EST 2U says Paul Lalljie to succeed Christopher 'Chip' Paucek as CEO - 2U announced a change of leadership to spearhead the next stage of its evolution as it focuses on improving operational efficiency and delivering profitable growth and cash flow. The Board of Directors has appointed Paul Lalljie, the company's current CFO, to succeed Christopher "Chip" Paucek as CEO and as a member of the Board of Directors, effective immediately. Additionally, Matt Norden, the company's Chief Legal Officer, will also assume the role of CFO. Paucek will remain an employee of the company through December 15, 2023, at which time he will transition to Special Advisor. Lalljie brings significant experience in finance management in the high-growth technology sector to his new role. Before joining 2U in 2019, he spent 18 years at Neustar, a billion-dollar information services business, where he served as CFO for nine years. During his tenure, Lalljie had global financial and operational responsibility for repositioning Neustar as an information services company. Norden has over a decade of experience at 2U and played a leadership role in the company's IPO in 2014 and in all subsequent capital markets and M&A activities. Prior to 2U, he was the General Counsel at TOMS Shoes.

08:01 EST Medavail announces agreement with ASP cares for deployment of ten M4 MedCenters - MedAvail announced that it has entered into an agreement with Pharmacy Fund 1 for the deployment of ten M4 MedCenter kiosks, which will be serviced by ASP Cares Pharmacy. Pharmacy Fund 1 also operates Oaklawn Pharmacy, which is a current MedAvail partner in Dallas, Texas. Per the terms of the agreement, the first three MedCenters are planned to be deployed at First Person Care Clinics in Las Vegas. All ten MedCenters are expected to be deployed in 2024. "We are excited to enter into this agreement with ASP Cares and deploy our first MedCenter kiosks in Las Vegas, a new market for us," stated Mark Doerr, Chief Executive Officer of MedAvail. "This agreement represents an expansion of our relationship with Daniel and the team at Oak Lawn Pharmacy. We have already initiated integration activities and anticipate efficient and timely deployments."

07:49 EST Li Auto unveils Li MEGA at Auto Guangzhou 2023 - Li Auto announced that the Company unveiled Li MEGA, its high-tech flagship family MPV, at the 21st Guangzhou International Automobile Exhibition. Li MEGA is open for reservations starting from November 17, 2023. Its retail price is expected to be below RMB600,000. The Company will officially launch Li MEGA in December 2023, with showroom models available in Li Auto retail stores starting in January 2024 and delivery of Li MEGA commencing in late February 2024. The orders for Li MEGA have exceeded 10,000 in 2 hours since the vehicle was available for reservations, demonstrating its outstanding appeal to family users. Each Li MEGA order requires a deposit of RMB5,000, which is refundable within a limited time period.

07:34 EST Yatra announces $5M share repurchase program - Yatra Online announced that its Board of Directors has approved a share repurchase program, pursuant to which the company is authorized to purchase up to $5M of its outstanding ordinary shares, par value $0.0001 per share, over an unlimited time period.

07:33 EST Canopy Growth: BioSteel gets Court approval of successful bids in sale process - Canopy Growth provided an update that pursuant to the proceedings under the Companies' Creditors Arrangement Act involving BioSteel Sports Nutrition, the Ontario Superior Court of Justice has approved two transactions to sell all or substantially all of the assets of BioSteel Canada and BioSteel Manufacturing, and that pending the closing of the transactions, Canopy Growth expects to realize proceeds which will improve the company's balance sheet.

07:21 EST SolGold board nominates Adrian van Barneveld as non-executive director - The Board of Directors of SolGold advises all shareholders and interested investors of the following changes to the Board of Directors of the Company. Two SolGold Directors, Mr. Liam Twigger and Mr. James Clare, have notified the Board that they will not seek re-election as Directors of the Company at the forthcoming Annual General Meeting of the Company to be held in December 2023. Mr. Twigger and Mr Clare have been an invaluable part of SolGold, serving as Chair and Non-Executive Director for three and five years, respectively. Following the AGM, the SolGold Board will undergo a reconstitution, appointing a new Chair and board committee memberships. The Board will begin a search for a new Chair of the Board immediately and will provide an update in due course. In line with SolGold's commitment to maintaining a solid and adaptive skill and experience base, the Board has resolved to nominate Mr. Adrian van Barneveld as a Non-Executive Director of SolGold, his appointment to be voted upon by shareholders at the AGM. Mr. van Barneveld has over 35 years of international experience across the resources and infrastructure sectors. He currently serves as General Manager, Australia West at a leading provider of minerals processing and associated infrastructure solutions to the global resources industry.

07:13 EST Virpax Pharmaceuticals receives noncompliance notification from Nasdaq - Virpax Pharmaceuticals announced that it received a notice from the Listing Qualifications Staff of Nasdaq stating that the company is not in compliance with Nasdaq Listing Rule 5250 as a result of the company's failure to timely file its quarterly report on Form 10-Q for the fiscal quarter ended, September 30 with the Securities and Exchange Commission.

07:12 EST Virpax Pharmaceuticals CEO Anthony Mack resigns - Virpax Pharmaceuticals announced that due to ongoing litigation it has accepted the resignation of Anthony Mack as CEO and chairman effective immediately. The board has appointed Gerald Bruce as CEO and Eric Floyd as chairman. Bruce has served as the company's executive VP of commercial operations since August 2017, as a member of the company's board since July 2021 and as the president and CEO of the company's wholly owned subsidiary, Novvae Pharmaceuticals since July 26.

07:09 EST Tharimmune announces 1-for-25 reverse stock split - Tharimmune will effect a 1-for-25 reverse stock split of its issued and outstanding shares of common stock. The reverse stock split was previously approved by Tharimmune stockholders at the Annual Meeting of Stockholders held on October 23, 2023, with the final ratio determined by the Company's Board of Directors. The reverse stock split will become effective at 4:01 p.m. Eastern time on November 20, 2023. Commencing with the opening of trading on The Nasdaq Capital Market on November 21, 2023, the Company's common stock will trade on a post-split basis under its existing trading symbol "THAR." Following the reverse stock split, the CUSIP number for the Company's common stock will be 432705200. As a result of the reverse stock split, every 25 shares of issued and outstanding common stock will be exchanged for 1 share of common stock, with any fractional shares being rounded up to the next higher whole share. Immediately after the reverse stock split becomes effective, the Company will have approximately 700,474 shares of common stock issued and outstanding. In addition, a proportionate adjustment will be made to outstanding equity-based awards and other equity rights. The reverse stock split is primarily intended to bring the Company into compliance with Nasdaq's $1.00 per share minimum bid price requirement for continued listing; however, no assurance can be given that such reverse stock split will enable the Company to regain compliance with the Nasdaq minimum bid price requirement.

07:07 EST Medicenna announces follow-up results from Phase 2b trial of bizaxofusp - Medicenna Therapeutics announced that a poster presentation and an oral summary highlighting longer term follow up results from the Phase 2b clinical trial of bizaxofusp, the Company's first-in-class IL-4R targeted therapy for the treatment of patients with recurrent glioblastoma, will be presented by Dr. Steven Brem, M.D. at the Society for Neuro-Oncology 2023 Annual Meeting, taking place from November 15-19, 2023, in Vancouver, Canada. 4-year follow up results: The data demonstrated that a single treatment with bizaxofusp increased median overall survival by 72% compared to the ECA. Overall survival for bizaxofusp-treated patients increased 370% at Year 1 and increased more than 50% at Year 2. Importantly, bizaxofusp doubled mOS irrespective of IL4R expression (high or low) compared to ECA. No systemic or clinically significant laboratory abnormalities were reported. Treatment-related adverse events were primarily neurological or aggravation of pre-existing neurological deficits due to rGBM

07:05 EST Day One announces tovorafenib FIREFLY-1 data published in Nature Medicine - Day One Biopharmaceuticals announced the publication of the registrational Phase 2 FIREFLY-1 trial results evaluating the investigational agent tovorafenib in patients with BRAF-altered, relapsed or progressive pediatric low-grade glioma, pLGG, in Nature Medicine. Subsets of the data will also be presented today in two oral plenary presentations at the 2023 Society for Neuro-Oncology, SNO, Annual Meeting in Vancouver, Canada. "The study results published in Nature Medicine demonstrate promising evidence with respect to the the impact of tovorafenib for children and young adults with BRAF-altered relapsed or progressive pLGG, a debilitating form of brain tumor that currently has no approved systemic therapies," said Dr. Samuel Blackman, co-founder and head of research and development, Day One. "We look forward to continued development of tovorafenib."

07:04 EST Missfresh receives delisting notice from Nasdaq - Missfresh Limited, as previously announced on August 3, 2023, and the transactions under the share transfer agreement, as previously announced on August 7, 2023, have been terminated. On November 15, 2023, the Nasdaq Hearings Panel notified the Company that the Panel has determined to delist the Company's securities from The Nasdaq Stock Market LLC and suspend trading in those securities effective at the open of trading on Friday, November 17, 2023. Nasdaq will complete the delisting by filing a Form 25 Notification of Delisting with the SEC, after applicable appeal periods have lapsed. The Company expects its American Depositary Shares to be eligible trade on the OTC Markets effective with the open of trading on Friday, November 17, 2023. This delisting and transition to the OTC Markets will not change the Company's obligation to file annual reports and certain other reports with the SEC under the applicable federal securities laws. The Company cautions the reader to read this press release in its entirety and refer to the Company's press releases and reports filed with the SEC, including the risks and uncertainties discussed therein, before making any investment decision

07:01 EST Novant Health to acquire three hospitals from Tenet Healthcare for $2.4B - Novant Health and Tenet Healthcare announced that they have signed a definitive agreement regarding the acquisition by Novant Health of three Tenet hospitals and affiliated operations in South Carolina. Under the terms of the agreement, Novant Health will purchase three hospitals, as well as associated physician practices and other related hospital operations from Tenet for approximately $2.4B. The transaction includes Hilton Head Hospital in Beaufort County, Coastal Carolina Hospital in Jasper County, and East Cooper Medical Center in Charleston County. The agreement also stipulates that Tenet's Conifer Health Solutions subsidiary will provide expanded revenue cycle management services to the three hospitals following completion of the transaction. The transaction is expected to be completed early next year, subject to customary regulatory approvals, clearances, and closing conditions.

06:35 EST Fisker announces new distribution strategy - Fisker announced that it delivered 107 vehicles on Thursday, Nov. 16. The company achieved this milestone by executing a new distribution strategy. This one-day total of deliveries equates to revenue of over $7.5M. "This result proves that our new distribution strategy is working," Chairman and CEO Henrik Fisker said. "We expect this pace of deliveries to accelerate, and we will provide frequent updates during the remainder of 2023. We are grateful to our customers for their patience as we conduct this ramp-up." Fisker has strategically improved its capabilities by establishing its own delivery locations globally, staffed by ever-growing numbers of Fisker employees. The company has also added multiple transportation logistics partners to quickly move Fisker Oceans to delivery locations so that they can be delivered to customers more rapidly. Customers who live within 60 miles of a Fisker fulfillment location can have their vehicle delivered through Fisker Direct, where a Fisker employee drives their Ocean directly to them for delivery, eliminating use of a vehicle transport. Fisker has increased overall process agility; many customers receive their car within four to seven days of completing their purchase, and in some cases on the same day when choosing the vehicle pickup option.

06:16 EST VIA Optronics announces corporate, management updates - VIA optronics AG announced several updates related to the ongoing internal review of the Company's internal controls and certain compliance incidents, the day-to-day management of its business and the Company's receipt of a listing extension from the New York Stock Exchange. As previously reported on Form 6-K as furnished to the SEC on August 9, 2023, VIA's Supervisory Board announced that it initiated a formal review of the Company's application of its internal compliance procedures, with the support of external advisors, and that it was investigating incidents regarding compliance with Company policies and business guidelines. The Supervisory Board appointed BDO AG Wirtschaftsprufungsgesellschaft and DLA Piper UK LLP to investigate the potential incidents and directed the Advisors to review compliance with Company policies and business guidelines from January 1, 2017 to December 31, 2022. While the investigation remains ongoing, preliminary findings indicate deviations from the Company's compliance procedures during the Investigation Period primarily involving the former CEO, Jurgen Eichner, and a limited number of other employees. Identified discrepancies occurred in areas such as expense recording and reimbursement, company credit card usage for personal transactions, inadequate documentation of vehicle usage, and irregularities in vacation days. The extent of the potential violations, and any response by the Company or others, remains uncertain. Chief Executive Officer Roland Chochoiek commented, "Our leadership is committed to completing a thorough review of the compliance incidents and our internal controls. The Company and the Supervisory Board are continuing to work with the Advisors to complete the investigation as soon as possible and will provide further updates once the investigation has been concluded. Unfortunately, the timing of the internal review process will result in a further delay of the filing of our form 20-F for the year ended December 31, 2022 with the U.S. Securities & Exchange Commission. We anticipate that the investigation will be concluded by the end of calendar year 2023 and that we will be able to file our form 20-F in early 2024." The Company takes these matters seriously and management is dedicated to expediting the filing process related to its form 20-F and interim financial statements for the six months ended June 30, 2023. In response to these developments, earlier this month the Supervisory Board placed founder and member of the Management Board, Jurgen Eichner, on leave until the internal review has been completed. In addition, the Company further announced that Bernd Wagner has been appointed as Interim Chief Financial Officer as Dr. Markus Peters has taken a leave of absence following a medical procedure. Mr. Wagner will assist with the completion of the internal review and filing of the Company's audited financial statements. He will not serve as a member of the Company's Management Board. Company management has proactively engaged with the New York Stock Exchange and has been granted an extended trading period by the exchange through May 16, 2024. The Company will work diligently to complete and file the delayed filing and any subsequent delayed filings prior to the expiry of the extended trading period, and NYSE will closely monitor the Company's progress while it remains on the NYSE late filer list.

06:03 EST BeiGene receives European Commission approval for BRUKINSA - BeiGene announced that the European Commission has granted marketing authorization for BRUKINSA in combination with obinutuzumab for the treatment of adult patients with relapsed or refractory follicular lymphoma who have received at least two prior lines of systemic therapy. This marks the fourth indication in the European Union for BRUKINSA, which is now approved to treat more patient populations in the EU than any other Bruton's tyrosine kinase inhibitor.

05:36 EST Astellas Pharma, Pfizer announce FDA approval of Xtandi sNDA - Astellas Pharma (ALPMY) and Pfizer (PFE) announced that the companies received an approval by the FDA of a supplemental new drug application for Xtandi, following FDA expedited development and review programs, based on results from the Phase 3 EMBARK trial. With this approval, Xtandi becomes the first and only androgen receptor signaling inhibitor approved by the FDA for the treatment of patients with nonmetastatic castration-sensitive prostate cancer, or nmCSPC, with biochemical recurrence at high risk for metastasis. Patients with nmCSPC with high-risk BCR may be treated with Xtandi with or without a gonadotropin-releasing hormone analog therapy.

05:30 EST PureTech Health entity Karuna Therapeutics announces results from KarXT trial - PureTech Health (PRTC) noted that its founded entity, Karuna Therapeutics (KRTX), announced results from its Phase 1b open-label, eight-week inpatient trial evaluating the effect of KarXT on 24-hour ambulatory blood pressure in adults with schizophrenia demonstrating that KarXT was not associated with increases in blood pressure. The primary endpoint in the trial was the change from baseline at week eight in 24-hour average ambulatory systolic blood pressure. In the trial, KarXT demonstrated a mean change from baseline to week eight in 24-hour ambulatory systolic blood pressure of -0.59 mmHg. The upper bound of the two-sided 95% confidence interval for the mean change from baseline to week 8 was 1.60 mmHg, thus ruling out a clinically meaningful increase in blood pressure. Daytime and nighttime systolic blood pressure measurements showed no meaningful change and were generally consistent with the 24-hour average. Additional vital sign measures collected in the trial, including 24-hour average diastolic blood pressure and heart rate, were consistent with prior trials of KarXT in schizophrenia. Further, KarXT was generally well tolerated, with a side effect profile consistent with prior trials in the EMERGENT program. PureTech is a founder of Karuna and co-inventor of the KarXT program. In September, Karuna announced the submission of a new drug application to the FDA for KarXT for the treatment of schizophrenia. If approved, KarXT will be the third therapeutic candidate to be taken from inception at PureTech to FDA regulatory approval.

05:18 EST XPeng presents X9 Large 7-seater MPV - XPeng presented its latest Smart EV model, the XPeng X9 Large 7-seater MPV, for the Chinese market at Auto Guangzhou 2023, with presale pricing starting from RMB 388,000.